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ABSTRACT
Introduction: Non-pharmacological therapies for
common chronic medical conditions in older patients
are underused in clinical practice. We propose a
protocol for the assessment of the evidence of non-
pharmacological interventions to prevent or treat
relevant outcomes in several prevalent geriatric
conditions in order to provide recommendations.
Methods and analysis: The conditions of interest
for which the evidence about efficacy of non-
pharmacological interventions will be searched include
delirium, falls, pressure sores, urinary incontinence,
dementia, heart failure, orthostatic hypotension,
sarcopaenia and stroke. For each condition, the
following steps will be undertaken: (A) prioritising
clinical questions; (B) retrieving the evidence
(MEDLINE, the Cochrane Library, CINAHL and
PsychINFO will be searched to identify systematic
reviews); (C) assessing the methodological quality of
the evidence (risk of bias according to the Cochrane
method will be applied to the primary studies retrieved
from the systematic reviews); (D) developing
recommendations based on the evidence (Grading of
Recommendations Assessment, Development and
Evaluation (GRADE) items—risk of bias, imprecision,
inconsistency, indirectness and publication bias—will
be used to rate the overall evidence and develop
recommendations).
Dissemination: For each target condition, at least
one systematic overview concerning the evidence of
non-pharmacological interventions will be produced
and published in peer-reviewed journals.
INTRODUCTION
The European population of older people
with multiple chronic diseases (multimorbid-
ity) is increasing steadily in parallel with the
rising population of people aged ≥65 years.1
Older multimorbid people are at high risk of
polypharmacy,2 inappropriate prescribing,3 4
adverse drug reactions5 and adverse drug
events.6 Polypharmacy, inappropriate pre-
scribing, adverse drug reactions and adverse
drug events in turn cause excessive drug
costs and excess healthcare utilisation;7 8
adverse drug reactions and adverse drug
events also cause signiﬁcant mortality.9 10
Drug therapy and non-drug therapies are
complementary in the management of older
people with multimorbidity. It is widely
acknowledged that non-pharmacological
therapies can be as effective and sometimes
more effective than drug therapy in the treat-
ment of several common chronic condi-
tions.11 12 Nevertheless, there is a widespread
Strengths and limitations of this study
▪ The strength of the Optimal Evidence-Based Non-
drug Therapies in Older People (ONTOP) project is
its extensive, comprehensive systematic overview
of reviews concerning non-pharmacological inter-
ventions for chronic geriatric conditions as well as
the provision of a Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
approach-based recommendation of the evidence
of non-pharmacological interventions.
▪ A limitation of the ONTOP recommendations is
that they are produced in isolation, that is, con-
sidering each geriatric condition in isolation,
rather than in combination. In multimorbid older
people with more than one geriatric condition,
the recommendation of particular non-drug ther-
apies may be more nuanced. In this sense, the
ONTOP recommendations may need to be
synthetised, avoiding repetitions when the same
intervention is effective in different conditions or
changing the recommendations, when the inter-
vention that is useful for one condition might be
contraindicated if the patient has another
condition.
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underuse of non-drug therapies, such as physiotherapy,
occupational therapy, speech and language therapy,
nutritional therapy and psychotherapy, in the treatment
of chronic diseases and conditions. Optimal manage-
ment of drug and non-drug therapy in older multimor-
bid persons usually requires specialist skills, but most
doctors who treat older people do not have specialist
training in Geriatric Medicine.13 14
To date, there is no widely used compendium of non-
pharmacological therapies for the common chronic
medical conditions of late life. This might contribute to
their underuse in clinical practice. To ﬁll this knowledge
gap, we present the Optimal Evidence-Based Non-drug
Therapies in Older People (ONTOP) project whose
principal aims are to: (A) undertake a literature search
of systematic reviews (SRs) concerning evidence-based
non-pharmacological treatments of the common
medical conditions affecting older people in order to
identify those treatments that are ﬁrmly evidence-based,
and (B) to deﬁne in bullet-point format the indications
and contraindications of non-pharmacological therapies
for which there is the strongest evidence base in each of
the chronic conditions.
The ONTOP project is part of a large European
Union funded research project called SENATOR
(Software ENgine for the Assessment & optimization of drug
and non-drug Therapy in Older persons; http://www.
senator-project.eu/) that aims to build a software engine
with the capacity to optimise non-pharmacological as
well as pharmacological therapy and simultaneously min-
imise adverse drug reactions, inappropriate prescribing,
polypharmacy and excessive cost in older patients with
multimorbidity. The efﬁcacy of SENATOR software will
be tested by a randomised controlled clinical trial, start-
ing in 2015.
METHODS
The conditions that will be evaluated in the ONTOP
project include delirium, falls, pressure sores, urinary
incontinence, dementia, heart failure, orthostatic hypo-
tension, sarcopaenia and stroke.
The following steps will be undertaken for each condi-
tion evaluated in the ONTOP project:
A. Formulating and prioritising clinical questions;
B. Retrieving the evidence using the SRs;
C. Assessing the methodological quality of the evidence;
D. Developing recommendations based on the
evidence.
Formulating and prioritising clinical questions
For each of the aforementioned conditions, the ONTOP
group will formulate and prioritise answerable clinical
questions using the PICO methodology, which speciﬁes
the Patient population, the Intervention of interest, the
Comparator and the Outcomes of interest.15 The outcome
component will be the driver in the formulation of each
clinical question and its importance should be based on
clinical relevance rather than on evidence. To identify rele-
vant outcomes, the ONTOP group will submit a list of out-
comes to an international expert advisory panel of
geriatricians for evaluation, discussion and rating.15 The
ONTOP group will revise or add other outcomes that may
be relevant for prioritising clinical questions. In a second
round of consultation, the panel will rate the clinical out-
comes as follows: critical (score 7–9), important but not
critical (score 4–6) or low importance (1–3). Only critic-
ally important outcomes will be considered relevant to
ONTOP recommendations.15
Retrieving the evidence from SRs
Inclusion criteria for SR
For each condition, to identify the abstracts of interest
we will prepare search strategies in the following data-
bases: Cochrane Database of Systematic Review,
PubMed, PsychInfo and CINAHL. Appropriate search
strategies for each electronic database will be developed.
In order to retrieve SRs, two criteria will be considered
for further evaluation of an abstract, that is, (A) a paper
generally deﬁned as a review, and (B) the mention of
any non-pharmacological intervention for the condition
of interest. For abstracts derived from the Cochrane
Library, only the second criterion will be applied.
Guidelines will be excluded but will be considered for
reference checking to identify potentially relevant SRs.
Full texts of relevant abstracts will then be obtained
and screened to identify SRs of interest based on (1) the
use of at least one medical literature database (eg,
MEDLINE) for evidence search; (2) the inclusion of at
least one primary study and (3) the use of at least one
non-pharmacological intervention for prevention or
treatment of the condition of interest. For papers
written in a language other than English, an attempt at
translation will be undertaken.
Pairs of reviewers will independently screen titles,
abstracts and full texts. Disagreement will be resolved by
discussion and, if necessary, by a third independent
reviewer.
The process of published study selection will be pre-
sented in a PRISMA ﬂow diagram (ﬁgure 1).
We will assess the methodological quality of each SR
using the AMSTAR (A Measurement Tool to Assess
Reviews) instrument. AMSTAR appraises the quality of
reviews using the following 11 items: duplicate study
selection and data extraction, comprehensive searching
of the literature, provision of a list of included and
excluded studies, provision of characteristics of included
studies, assessment of methodological quality of
included studies, appropriate methods for combining
results of studies and for assessing publication bias, and
consideration of conﬂict of interest statement.16 Two
reviewers will independently evaluate the quality of the
SRs and disagreement will be resolved by consensus.
Where there are multiple reviews that answer the same
clinical question, the reviews with the highest score will
be prioritised in the evidence retrieval and assessment.
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Inclusion criteria for primary studies
From the included SRs, we will identify and consider any
comparative study, either randomised or non-
randomised, that investigated any non-pharmacological
intervention to prevent and/or treat an ONTOP condi-
tion, as appropriate. In some conditions, for example,
delirium, both prevention and treatment will be evalu-
ated; in other conditions, for example, falls, only preven-
tion will be considered or treatment only, as in the case
of dementia. Primary studies will be excluded if they
were observational studies or before-after studies with
historical controls.
Data extraction and management
Pairs of reviewers will perform data extraction from
primary studies independently. Data will be extracted
onto study-speciﬁc data extraction forms. Information
collected will include trial characteristics (year of publi-
cation, country of origin of the study, methodological
quality items of the study), patients’ characteristics
(number of participants, age, gender), intervention
characteristics, comparator characteristics, type of
outcome and outcome measures.
Measures of treatment effect
For binary outcome measures, we will use risk ratios or
ORs along with their 95% CIs. For continuous outcome
measures, mean difference with 95% CI will be used to
estimate the summary effect; standardised mean differ-
ence will be used when data are measured on different
scales.
Assessment of heterogeneity
We will assess heterogeneity according to the approach
described in Section 9.5 of the Cochrane Handbook.17
Where a meta-analysis is possible with at least two
studies, we will use the χ2 test and I2 statistic to assess
heterogeneity. We will consider heterogeneity to be stat-
istically signiﬁcant if the p value is less than 0.1. The
Cochrane Handbook guide to the interpretation of the
Figure 1 Study screening
process (SR, systematic review).
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I2 statistic will be used: 0–30% might not be important,
30–60% may represent moderate heterogeneity, 50–75%
may represent substantial heterogeneity, and 75–100%
represents considerable heterogeneity.
Data synthesis
We will carry out data synthesis using Review Manager
software according to the Cochrane Collaboration statis-
tical guidelines (RevMan 2014). As we expect some level
of heterogeneity between studies due to the diversity of
the non-pharmacological interventions, a random-effects
model will be used as a primary method of
meta-analysis.
Assessing the methodological quality of the evidence
The retrieved evidence will be assessed using the
GRADE (Grading of Recommendations Assessment,
Development and Evaluation) approach. For each clin-
ical question, evidence proﬁles based on the results of
the treatment effect (of a meta-analysis or a single
primary study) will be prepared. The GRADE system
classiﬁes the quality of evidence into four categories: (1)
high (further research is very unlikely to change our
conﬁdence in the estimate of the effect), (2) moderate
(further research is likely to have an important impact
on our conﬁdence in the effect and may change the esti-
mate), (3) low (further research is very likely to have an
important impact on our conﬁdence in the estimate of
effect and is likely to change the estimate) and (4) very
low (any estimate of effect is very uncertain).18
The following factors that affect this rating of quality
will be considered: (1) study design and execution or
risk of bias,19 (2) the consistency of results,20 (3) the dir-
ectness of the evidence,21 (4) the precision of the esti-
mate of the effect22 and (5) the likelihood of
publication bias.23
In case of non-randomised studies, the following three
factors that may lead to upgrading the quality of evi-
dence will be considered: (1) a strong or very strong
association, (2) a dose–effect relationship, and (3) all
plausible confounding may be working to reduce the
demonstrated effect or increase the effect if no effect
was observed.24
Risk of bias assessment
Assessment of risk of bias for all the included trials will
be carried out using criteria from the Cochrane Handbook
for Systematic Reviews of Interventions. We will assess studies
according to random sequence generation, allocation
concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome
data, selective reporting and other potential items that
can be a source of bias. We will assign risk of bias to one
of three categories on the basis of the reviewer’s judge-
ment, that is, low risk, unclear risk and high risk. Given
that participants and personnel cannot always be
blinded due to the nature of the non-pharmacological
interventions, performance bias will usually not be used
for downgrading the level of evidence within the risk of
bias assessment.
From evidence to recommendation
Determining the net health benefit
The ONTOP group will discuss and evaluate the net
health beneﬁt based on the anticipated balance of bene-
ﬁts and harms across all clinically critical outcomes. For
each clinical question, a Summary of Findings (SoF)
table will be produced taking into account the gathered
evidence and the quality of the evidence. The SoF will
be used to move from evidence to recommendations
and to ensure that the ONTOP group uniformly consid-
ered the quality of the evidence, the certainty about the
balance of beneﬁts versus harms, the similarity in
patients’ values and preferences and the costs of an
intervention compared with the available alternatives.25
The overall quality of the evidence will be determined
by the lowest quality of evidence for each of the critical
outcomes.26
The ONTOP group will not perform retrieval and
formal ratings of the quality of economic evidence. Any
economic consideration will be based on available
guidelines.
Grading the strength of a recommendation
The strength of a recommendation will be categorised
as strong or weak. It will be determined by the following
factors: the quality of evidence, the balance between
desirable effects and undesirable ones, the values and
preferences, and the resources and costs. The strength
of recommendation will be considered strong when the
ONTOP group is conﬁdent that the desirable effects of
adherence to the recommendation outweigh the
undesirable effects. High or moderate quality of evi-
dence supports strong recommendations when this is
also supported by other considerations such as the base-
line risk of the population of interest, availability of the
service and accessibility to care and costs.
The strength of recommendation will be considered
weak when the balance of beneﬁt and harm is uncertain
(quality of evidence is low or very low), or when values
and preferences are uncertain or when much higher
costs are envisaged.27
DISCUSSION
Non-pharmacological interventions in older people can
be just as important as pharmacological therapies to
treat chronic conditions. For instance, in dementia, psy-
chotropic medications are used to reduce the frequency
and severity of behavioural symptoms, but they provide
modest symptom control28 and there are several indica-
tions of frequent and important adverse effects.28
Non-pharmacological interventions might provide a
valuable alternative to treat behavioural disturbances,
but they are potentially underused in clinical practice.29
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The ONTOP project will provide a number of advan-
tages to researchers, clinicians and guideline developers.
First, clinicians and healthcare providers currently
often suffer from an information overload. SRs are con-
sidered as a tool that provide evidence synthesis covering
almost all areas in medicine and healthcare. However,
the number and variety of SRs is growing rapidly and
there are concerns that for a single topic several SRs can
often be identiﬁed.30 31 The project will perform
updated systematic overviews concerning the non-
pharmacological interventions to treat or prevent clinic-
ally relevant outcomes of chronic conditions affecting
older people.
Second, since it is generally accepted that non-
pharmacological interventions are not used sufﬁciently
in clinical practice, there is a need to address this deﬁ-
ciency. One of the reasons for this situation may be that
there is no complete compendium of known non-
pharmacological interventions for the common geriatric
conditions to be reviewed by the ONTOP group. The
results from this project will provide the clinical practi-
tioner with a comprehensive list of evidence-based non-
pharmacological interventions.
Third, the evidence systematically retrieved from the
medical literature will be evaluated using the GRADE
method, which provides a systematic and transparent
framework for prioritising clinical questions and deter-
mining the outcomes of interest, summarising the evi-
dence that addresses a question, and moving from the
evidence to a treatment recommendation or decision.
Potential problems and solutions
Currently, there are sufﬁcient numbers of SRs being
published in the medical literature. It is estimated that
there are 11 reviews and 75 trials being published every
day.32 We opted to look for the evidence based on SRs,
as most of the interventions are covered by SRs.
However, when the evidence from the SRs is limited, we
will change our search to primary studies by performing
a standard SR. Conversely, we expect to retrieve a consid-
erable number of SRs in some conditions such as
dementia. In this case, we will limit the search period to
the last 5 years. Where SRs are not updated, we will
perform basic SRs.
Dissemination: For each target disease or condition, a
systematic overview concerning the evidence of non-
pharmacological interventions will be produced and
published in peer-reviewed journals.
Current status of the ONTOP project: The project started
in October 2012 and is due to be completed in October
2017. The search strategies and data collection regard-
ing the evidence for the following geriatric conditions:
delirium, dementia, urinary incontinence, falls and pres-
sure ulcers has been undertaken.
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